Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 229 results
A minimalist illustration of a surgical robot arm and scalpel on a dark background.

Jul 16, 2026

Japan overhauls healthcare and life sciences with Nvidia AI

Japan is set to revolutionize its healthcare and life sciences sectors through the integration of AI technologies, particularly leveraging Nvidia's innovations.Recent discussions led by Nvidia CEO Jensen Huang highlighted Japan's commitment to advancing medical technology with AI-driven solutions. The country is actively implementing autonomous surgical robots, AI-enhanced imaging systems, and innovative drug discovery platforms. A notable initiative is the Tokyo-1 consortium, which unites major
A laboratory vial containing a drug compound in a dimly lit lab setting.

Jul 15, 2026

Bora Pharmaceuticals and Insilico Medicine Strike a $2.5 Billion AI Alliance

Bora Pharmaceuticals and Insilico Medicine have entered a significant partnership aimed at revolutionizing AI-driven drug development, with a potential value exceeding $2.5 billion.This collaboration, announced during BIO Asia-Taiwan, marks a pivotal shift in the pharmaceutical landscape, focusing on integrating AI not just in drug discovery but also in manufacturing processes. Insilico's Pharma.AI platform, which encompasses tools for target discovery and clinical insights, will be paired with
A minimalist representation of a TNIK inhibitor molecule in a dark color scheme.

Jul 15, 2026

Insilico & Bora Partner on AI Drug Discovery

Insilico Medicine and Bora Pharmaceuticals have formed a strategic alliance aimed at enhancing AI-driven drug discovery and development.The partnership leverages Insilico's Pharma.AI platform, which integrates target identification, generative chemistry, and multi-parameter optimization. Since its inception in 2021, this platform has successfully generated 31 preclinical candidates, with 13 receiving IND approvals. Notably, one standout asset is ISM018_055, an AI-generated TNIK inhibitor current
A vial of a drug compound in a dimly lit laboratory setting.

Jul 15, 2026

Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development

Insilico Medicine and Bora Pharmaceuticals are poised to form a strategic alliance aimed at revolutionizing drug discovery and development through AI technologies.The proposed collaboration is anticipated to be valued at over $2.5 billion if fully realized. It aims to integrate Insilico's Pharma.AI platform—which specializes in target discovery, generative chemistry, and molecule optimization—with Bora's extensive capabilities in drug development, manufacturing, and commercialization. This partn
A minimalist illustration of a pill bottle and an AI chip on a dark background.

Jul 15, 2026

Bora, Insilico Launch Multi-Target AI Pharma Alliance

Insilico Medicine has formed a strategic alliance with Bora Pharmaceuticals to integrate AI into drug discovery and development.Insilico Medicine, known for its generative AI-driven approach to drug discovery, has partnered with Bora Pharmaceuticals to create a multi-target alliance. This collaboration aims to merge Insilico’s Pharma.AI platform with Bora’s extensive capabilities in global development, manufacturing, and commercialization. The goal is to innovate drug development by linking AI-e
A molecule in a petri dish in a dimly lit lab

Jul 15, 2026

Insilico and Bora Pharmaceuticals forge strategic AI-driven drug discovery alliance

Insilico Medicine has announced a strategic alliance with Bora Pharmaceuticals aimed at revolutionizing drug discovery through AI integration.The partnership will leverage Insilico's Pharma.AI platform, which encompasses target discovery and molecule optimization, alongside Bora's extensive capabilities in drug development and manufacturing. This collaboration aspires to create a comprehensive model that not only designs novel molecules but also streamlines their development and delivery to addr
A vial of a drug compound in a dimly lit laboratory setting

Jul 15, 2026

OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B

Miles Wang, an OpenAI researcher known for his contributions to AI in scientific discovery, is reportedly leaving the organization to establish a new startup dedicated to AI-driven drug discovery. This venture is anticipated to be valued at $2 billion, with plans to raise approximately $200 million, primarily led by Lightspeed Venture Partners.The proposed startup aims to leverage AI models to enhance the drug discovery process, potentially identifying new applications for existing medications,
A minimalist representation of a drug molecule in flat design.

Jul 15, 2026

OpenAI Researcher Miles Wang Eyes $2B AI Drug Discovery Startup

OpenAI researcher Miles Wang is poised to launch an AI-driven drug discovery startup valued at $2 billion, marking a significant trend in biotech investment.Wang's venture is reportedly in advanced discussions with Lightspeed Venture Partners, which aims to lead a funding round that could become one of the largest in the biotech sector. This initiative highlights the growing investor confidence in AI's ability to transform pharmaceutical development, particularly in drug discovery, which traditi
A molecular model on a lab bench in a research laboratory

Jul 14, 2026

Chai Discovery Raises $400 Million Series C To Advance AI-Driven Molecular Design

Chai Discovery has successfully secured $400 million in Series C funding, propelling its AI-driven molecular design platform toward enhanced drug discovery capabilities.The financing round, which values the company at $3.8 billion, was spearheaded by Index Ventures and included significant participation from other notable investors such as Kleiner Perkins, Sequoia Capital, and Bain Capital Ventures. Existing backers, including OpenAI and Thrive Capital, also contributed to this substantial inves
Flat illustration of a cancer cell and in silico model

Jul 14, 2026

Biotech companies tout benefits of AI-assisted drug development

Biotechnology firms are increasingly integrating artificial intelligence (AI) into drug development processes, showcasing its potential to revolutionize research methodologies and outcomes. At the Kadans Oncology Summit in Paris, discussions highlighted various applications of AI, particularly in drug target discovery and the development of preclinical cancer models.One notable innovation is the use of in silico models, which aim to replace traditional cellular and animal testing methods. Paul D
A minimalist representation of biotechnology tools and health tech collaboration.

Jul 14, 2026

AusBiotech and Oktopi announce partnership to boost Australian life sciences

AusBiotech has formed a strategic partnership with Oktopi to enhance support for its members in the Australian life sciences sector.The collaboration aims to provide AusBiotech members with access to Oktopi's AI-driven platform at discounted rates, further enriching the organization's Business Solutions Program. This initiative will connect professionals in biotechnology, medical technology, and health tech with customized tools and pricing to facilitate medicine development.Rebekah Cassidy, CEO
A flat illustration of a pill and a brain silhouette on a solid background.

Jul 13, 2026

Insilico Medicine and CMS Enter $177 Million AI-Powered Drug Discovery Collaboration

Insilico Medicine and China Medical System Holdings Limited (CMS) have entered a significant $177 million collaboration focused on AI-driven drug discovery for central nervous system disorders. This partnership builds on their initial collaboration just three months prior, highlighting a strong and productive relationship.The agreement facilitates a joint effort in advancing a drug discovery program that combines Insilico's generative AI capabilities, particularly its PandaOmics platform, with C